Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: Study protocol for a pragmatic randomized controlled trial (CYSCEtrial)

Trials

Volumn 16, Issue 1, 2015, Pages

  Berm, Elizabeth J J ^a   Hak, Eelko ^a,b   Postma, Maarten ^a,b   Boshuisen, Marjolein ^c   Breuning, Laura ^d   Brouwers, Jacobus R B J ^a,e   Dhondt, Ton ^f   Jansen, Paul A F ^e   Kok, Rob M ^g   Maring, Jan G ^h   Van Marum, Rob ^i,j   Mulder, Hans ^k   Voshaar, Oude Richard C ^b   Risselada, Arne J ^k   Venema, Harry ^f   Vleugel, Liesbeth ^f   Wilffert, Bob ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Lentis   (Netherlands)

^d REINIER VAN ARKEL GROUP   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f Department of Geriatric Medicine and Expertise Centere Pharmacotherapy in Old Persons UMC Utrecht ^*  (Netherlands)

^g PARNASSIA PSYCHIATRIC INSTITUTE   (Netherlands)

^h Bethesda Hospital   (Netherlands)

ⁱ JEROEN BOSCH HOSPITAL   (Netherlands)

^j VU UNIVERSITY AMSTERDAM   (Netherlands)

^k Wilhelmina Ziekenhuis   (Netherlands)

more..

Author keywords

CYP2D6; Depression; Nortriptyline; Pharmacogenetics; Venlafaxine

Indexed keywords

CYTOCHROME P450 2D6; NORTRIPTYLINE; VENLAFAXINE; ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DSM-IV; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MENTAL HEALTH CENTER; MIDDLE AGED; MULTICENTER STUDY; NETHERLANDS; PATIENT CARE; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; CLINICAL PROTOCOL; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; GENETICS; SAMPLE SIZE;

ANTIDEPRESSIVE AGENTS; CLINICAL PROTOCOLS; COST-BENEFIT ANALYSIS; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER, MAJOR; GENOTYPE; HUMANS; NORTRIPTYLINE; PHARMACOGENETICS; SAMPLE SIZE; VENLAFAXINE HYDROCHLORIDE;

EID: 84924353620     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/s13063-015-0561-0     Document Type: Article

References (35)

1. Brown PJ, Roose SP. Age and anxiety and depressive symptoms: the effect on domains of quality of life. Int J Geriatr Psychiatry. 2011;26(12):1260-6.
2. Beekman AT, Copeland JR, Prince MJ. Review of community prevalence of depression in later life. Br J Psychiatry. 1999;174:307-11.
3. Luppa M, Sikorski C, Luck T, Ehreke L, Konnopka A, Wiese B, et al. Age- and gender-specific prevalence of depression in latest-life - systematic review and meta-analysis. J Affect Disord. 2012;136(3):212-21.
4. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2197-223.
5. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
6. Kok RM, Nolen WA, Heeren TJ. Efficacy of treatment in older depressed patients: a systematic review and meta-analysis of double-blind randomized controlled trials with antidepressants. J Affect Disord. 2012;141(2-3):103-15.
7. Reuben D, Herr K, Pacala J, Pollock B, Potter J, Semla T. Depression. Geriatrics at your fingertips. 16th ed. American Geriatrics Society; 2014.
8. Landelijke stuurgroep multidiciplinaire richtlijnontwikkeling in de GGZ. Dutch Guideline Depression (Addendum Elderly) Addendum Ouderen bij MDR derpessie. 2008.
9. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5(1):6-13.
10. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9(5):442-73.
11. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44(6):195-235.
12. de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics. 2006;47(1):75-85.
13. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013.
14. Swen JJ, Nijenhuis M, de Boer A, Grandia L, der Zee AH M-v, Mulder H, et al. Pharmacogenetics: from bench to byte - an update of guidelines. Clin Pharmacol Ther. 2011;89(5):662-73.
15. Swen JJ, Wilting I, de Goede AL, Grandia L, Mulder H, Touw DJ, et al. Pharmacogenetics: from bench to byte. Clin Pharmacol Ther. 2008;83(5):781-7.
16. Kirchheiner J, Seeringer A, Viviani R. Pharmacogenetics in psychiatry - a useful clinical tool or wishful thinking for the future? Curr Pharm Des. 2010;16(2):136-44.
17. Hodgson K, Tansey K, Dernovsek MZ, Hauser J, Henigsberg N, Maier W, et al. Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. J Psychopharmacol. 2014;28(2):133-41.
18. Schulz KF, Altman DG, Moher D. CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med. 2010;7(3):e1000251.
19. Dalen P, Dahl ML, Bernal Ruiz ML, Nordin J, Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther. 1998;63(4):444-52.
20. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC: Author; 2000.
21. Flockhart DA. Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine (2007). 2013. Available at: http://medicine.iupui.edu/clinpharm/ddis/table.aspx. Accessed 8 August 2014
22. de Boer T, Wieling J, Meulman E, Reuvers M, Renkema G, den Daas I, et al. Application of dried blood spot sampling combined with LC-MS/MS for genotyping and phenotyping of CYP450 enzymes in healthy volunteers. Biomed Chromatogr. 2011;25(10):1112-23.
23. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-9.
24. Hakkaart-Van Roijen L, van Straten A, Donker M, Tiemens B. Manual Trimbos/iMTA questionnaire for costs asscociated with psychiatric ilness (TiC-P) (in Dutch). 2002.
25. Berm EJ, Brummel-Mulder E, Paardekooper J, Hak E, Wilffert B, Maring JG. Determination of venlafaxine and O-desmethylvenlafaxine in dried blood spots for TDM purposes, using LC-MS/MS. Anal Bioanal Chem. 2014;406(9-10):2349-53.
26. Berm EJJ, Paardekooper J, Brummel-Mulder E, Hak E, Wilffert B, Maring JG. A simple dried bloodspot method for therapeutic drug monitoring of the tricyclic antidepressants amitriptyline, nortriptyline, imipramine, clomipramine, and their active metabolites using LC-MS/MS. Talanta Advance online publication. doi:10.1016/j.talanta.2014.10.041.
27. Edelbroek PM, van der Heijden J, Stolk LM. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther Drug Monit. 2009;31(3):327-36.
28. Uher R, Farmer A, Henigsberg N, Rietschel M, Mors O, Maier W, et al. Adverse reactions to antidepressants. Br J Psychiatry. 2009;195(3):202-10.
29. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy. 1990;16(3):199-8
30. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573-83.
31. Jurgens G, Jacobsen CB, Rasmussen HB, Werge T, Nordentoft M, Andersen SE. Utility and adoption of CYP2D6 and CYP2C19 genotyping and its translation into psychiatric clinical practice. Acta Psychiatr Scand. 2012;125(3):228-37.
32. Skoog I. Psychiatric disorders in the elderly. Can J Psychiatry. 2011;56(7):387-97.
33. March JS, Silva SG, Compton S, Shapiro M, Califf R, Krishnan R. The case for practical clinical trials in psychiatry. Am J Psychiatry. 2005;162(5):836-46.
34. Sangkuhl K, Stingl JC, Turpeinen M, Altman RB, Klein TE. PharmGKB summary: venlafaxine pathway. Pharmacogenet Genomics. 2014;24(1):62-72.
35. Wille SM, Cooreman SG, Neels HM, Lambert WE. Relevant issues in the monitoring and the toxicology of antidepressants. Crit Rev Clin Lab Sci. 2008;45(1):25-89.